- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00003156
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent or refractory cancer of the uterus.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES: I. Estimate the antitumor activity of topotecan in patients with recurrent or refractory carcinosarcoma of the uterus who have failed standard therapy. II. Determine the nature and degree of toxic effects of topotecan in these patients.
OUTLINE: Patients receive topotecan IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for a minimum of 1 course in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease continue treatment for at least three courses. Patients are followed every 4 months for 2 years, every 6 months for 3 years, and then periodically thereafter until death.
PROJECTED ACCRUAL: Approximately 25-40 patients will be accrued for this study within 2 years.
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Center - Calgary
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, États-Unis, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Gatos, California, États-Unis, 95032
- Community Hospital of Los Gatos
-
Orange, California, États-Unis, 92868
- Chao Family Comprehensive Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20307-5000
- Walter Reed Army Medical Center
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
Chicago, Illinois, États-Unis, 60637
- University of Chicago Cancer Research Center
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202-5265
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- Radiation Oncology Branch
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Tufts University School of Medicine
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65203
- Ellis Fischel Cancer Center - Columbia
-
Kansas City, Missouri, États-Unis, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
New York
-
Albany, New York, États-Unis, 12208
- Cancer Center of Albany Medical Center
-
Brooklyn, New York, États-Unis, 11203
- State University of New York Health Science Center at Brooklyn
-
Manhasset, New York, États-Unis, 11030
- North Shore University Hospital
-
Stony Brook, New York, États-Unis, 11790-7775
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, États-Unis, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, États-Unis, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- Barrett Cancer Center, The University Hospital
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland, Ohio, États-Unis, 44106-5065
- Ireland Cancer Center
-
Columbus, Ohio, États-Unis, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73190
- University of Oklahoma College of Medicine
-
Tulsa, Oklahoma, États-Unis, 74136
- CCOP - Sooner State
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, États-Unis, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania Cancer Center
-
Wynnewood, Pennsylvania, États-Unis, 19096
- CCOP - MainLine Health
-
-
South Carolina
-
Spartanburg, South Carolina, États-Unis, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38117
- CCOP - Baptist Cancer Institute
-
Nashville, Tennessee, États-Unis, 37203
- Brookview Research, Inc.
-
-
Texas
-
Dallas, Texas, États-Unis, 75235-9154
- Simmons Cancer Center - Dallas
-
Temple, Texas, États-Unis, 76508
- CCOP - Scott and White Hospital
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05401
- Fletcher Allen Health Care
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Cancer Center, University of Virginia HSC
-
-
Washington
-
Seattle, Washington, États-Unis, 98195-6043
- University of Washington Medical Center
-
Tacoma, Washington, États-Unis, 98405
- Tacoma General Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory carcinosarcoma (mixed mesodermal tumors) of the uterus Measurable disease
PATIENT CHARACTERISTICS: Age: Not specified Performance Status: GOG 0-2 Life Expectancy: Not specified Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3 times ULN Alkaline phosphatase no greater than 3 times ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance greater than 20 mL/min Other: No invasive malignancies within the past 5 years except nonmelanomatous skin cancer No significant infection
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy Chemotherapy: At least 3 weeks since prior chemotherapy and recovered No prior topotecan or camptothecin therapy No more than 1 prior chemotherapy regimen (either single or combination chemotherapy) Endocrine therapy: At least 3 weeks since prior endocrine therapy Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery: Prior surgery allowed and recovered
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000065948
- GOG-130D
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur chlorhydrate de topotécan
-
Centre Francois BaclesseGlaxoSmithKline; Centre d'Etudes et de Recherche pour l'Intensification du...RésiliéCancer | Chimiothérapie | Rechute | OvaireFrance